BOSTON — Eight years after the ALS Ice Bucket Challenge went viral across social media and raised hundreds of millions of dollars for research, a Cambridge company is on the brink of a major breakthrough for ALS patients.
Amylyx Pharmaceuticals should receive word in the coming week from the U.S. Food and Drug Administration on whether the feds will approve the local firm’s drug treatment for the relentlessly progressive and fatal neurodegenerative disorder Amyotrophic Lateral Sclerosis, or ALS.
AMX0035, which has already been approved in Canada, is the first treatment funded by ALS Ice Bucket Challenge donations that’s being considered for approval by the FDA.
